WithdrawnPhase 1

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Stopped: IRB did not approve

0Started 2026-02

Plain-language summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-45 * Body mass index(BMI) \> 30 * Diagnosis of PCOS * Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone Exclusion Criteria: * Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device * Letrozole, clomiphene citrate, FSH therapy * Androgen receptor blockers * 5α reductase inhibitors * Insulin * Hysterectomy * Endometrial ablation

What they're measuring

Number of appropriate weekly dose

Timeframe: 4 weeks

Number of days on therapy

Timeframe: 4 weeks

Trial details

NCT IDNCT06222437

SponsorMethodist Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02

View on ClinicalTrials.gov More Polycystic Ovary Syndrome trials